NCT05246345
Recruiting
Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
Enrollment
50 pts
Location
France
Sponsor
University Hospital, Clermont-...
NCT05947851 Phase 3
Recruiting
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Enrollment
735 pts
Location
United States, Argen...
Sponsor
Merck Sharp & Dohme LLC